Gene: BGN
Official Full Name: biglycanprovided by HGNC
Gene Summary: This gene encodes a member of the small leucine-rich proteoglycan (SLRP) family of proteins. The encoded preproprotein is proteolytically processed to generate the mature protein, which plays a role in bone growth, muscle development and regeneration, and collagen fibril assembly in multiple tissues. This protein may also regulate inflammation and innate immunity. Additionally, the encoded protein may contribute to atherosclerosis and aortic valve stenosis in human patients. This gene and the related gene decorin are thought to be the result of a gene duplication. [provided by RefSeq, Nov 2015]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
GP00358 | BGN gRNA2 KO plasmid | BGN | $850 | |||
GP00359 | BGN gRNA1 KO plasmid | BGN | $850 | |||
KO04971 | BGN Knockout cell line (HeLa) | Human | BGN | 1:3~1:6 | Negative | Online Inquiry |
BGN Gene Knockout Cell Lines are specialized biological research tools designed for the targeted ablation of the BGN gene, which encodes for biglycan, a small leucine-rich proteoglycan involved in extracellular matrix structure and cellular signaling. These cell lines allow researchers to elucidate the functional roles of BGN in various biological processes, including cell proliferation, differentiation, and matrix development.
The primary mechanism of action involves CRISPR/Cas9 technology, which enables precise editing of the genome. By creating knockout cells, researchers can study the phenotypic consequences of the absence of the BGN gene, thus providing insight into its role in health and disease. This technology not only enhances gene editing efficiency but also reduces off-target effects, making it an invaluable tool in functional genomics.
The scientific importance of BGN Gene Knockout Cell Lines is underscored by their wide-ranging applications in both basic and translational research. They can be utilized in studies related to fibrosis, osteogenesis, and cardiovascular diseases, helping researchers identify potential therapeutic targets. In clinical settings, these cell lines facilitate drug screening and biomarker discovery, contributing to more personalized medicine approaches.
What sets our BGN Gene Knockout Cell Lines apart from alternatives is their rigorous validation for gene editing accuracy and cellular functionality. Each cell line is extensively characterized, ensuring reproducibility and reliability across experiments. Furthermore, our product supports a broad array of assay types, increasing experimental flexibility and data robustness.
For researchers and clinicians alike, the value of BGN Gene Knockout Cell Lines lies in their capacity to accelerate discovery and innovation in understanding complex diseases. As a part of our commitment to advancing scientific research, [Company Name] has extensive experience in developing high-quality biological products, ensuring our offerings meet the highest standards of scientific rigor and usability.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.